SUPN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.04% compare to its pairs and should correct upwards.

Stats
Šios dienos apimtis	2.64M
Vidutinė apimtis	534 925
Rinkos kapitalizacija	1.47B
EPS	$0.00230 ( Q1 \| 2024-05-08 )
Kita pelno data	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-92.24 (Sector) 42.63 (Industry) 0
ATR14	$0.0210 (0.08%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX -1.40%

AKAN -3.75%

ALIM 0.54%

AMPH -0.87%

AMYT 0.00%

ANIP 0.94%

AQST 0.39%

ASRT -5.34%

ATNX 0.00%

AVDL -1.75%

AYTU 0.00%

BFRI -2.39%

BGXX -34.22%

CLVR -2.22%

COLL -0.74%

CPIX 0.66%

CRDL 1.00%

CRON -0.43%

CYTH 5.83%

DCPH 0.00%

DERM 9.73%

DRRX -5.49%

DVAX -1.23%

EGRX 11.55%

EMBC 0.32%

EMBCV -9.33%

EOLS -0.73%

ESPR -3.90%

EVOK 5.48%

FLGC 6.71%

FLXN 0.00%

GHSI -0.35%

HCM -1.83%

HROW -0.52%

HUGE -4.71%

IMCC 2.20%

INCR 2.03%

IRWD 5.16%

ITCI -3.51%

IXHL 10.53%

JUPW 11.76%

KALA 9.92%

KIN 0.11%

KMDA -1.78%

LNTH -1.25%

NBIX 2.50%

NEPT 0.00%

NLTX 1.45%

OGI -3.75%

OPTN -3.70%

ORGO 6.06%

PAHC -2.50%

PCRX 2.51%

PETQ -0.45%

PLXP 0.00%

PPD 0.00%

PROC -0.40%

PRPH -2.11%

PTPI 2.69%

RDHL -2.58%

RDUS 4.30%

REPH -0.48%

RGC -5.88%

RMTI 0.00%

SCTL 0.92%

SCYX -1.48%

SIGA 3.13%

SISI -13.33%

SNDL -1.04%

SNOA 1.05%

SSIC 1.03%

SUPN -0.45%

SXTC -2.24%

THTX 0.00%

TKNO -1.44%

TLGT -13.85%

TLRY -4.05%

TXMD -7.47%

TYHT -3.90%

UPC -1.97%

VTRS 1.43%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Bhatt Padmanabh P.	Buy	14 491	Common Stock
2024-03-21	Bhatt Padmanabh P.	Sell	14 491	Employee Stock Option (Right to Buy)
2024-03-21	Bhatt Padmanabh P.	Sell	14 491	Common Stock
2024-03-20	Bhatt Padmanabh P.	Sell	400	Employee Stock Option (Right to Buy)
2024-03-20	Bhatt Padmanabh P.	Buy	400	Common Stock

INSIDER POWER
38.21
Last 100 transactions
Buy: 802 366 \| Sell: 356 762

Koreliacija (AI algo v.1.1b): Undervalued: 0.04% $26.76 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.50 (neutral)

Trumpas: -0.26 (neutral)

Signal:(34.293) Neutral

Supernus Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ORGS	0.887
VTYX	0.868
CRTD	0.863
XRTX	0.863
SOUN	0.859
BRKR	0.857
LNW	0.848
ARQQ	0.846
ICLR	0.846
BTF	0.84

10 Labiausiai neigiamai susiję koreliacijos
SABR	-0.835

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Supernus Pharmaceuticals Koreliacija - Valiuta/Žaliavos

-0.62
( weak negative )

-0.56
( weak negative )

0.00
( neutral )

-0.37
( neutral )

0.00
( neutral )

-0.46
( neutral )

Supernus Pharmaceuticals Finansinės ataskaitos

Annual	2023
Pajamos:	$607.52M
Bruto pelnas:	$438.88M (72.24 %)
EPS:	$0.0241

FY	2023
Pajamos:	$607.52M
Bruto pelnas:	$438.88M (72.24 %)
EPS:	$0.0241

FY	2022
Pajamos:	$667.24M
Bruto pelnas:	$580.02M (86.93 %)
EPS:	$1.130

FY	2021
Pajamos:	$579.78M
Bruto pelnas:	$504.71M (87.05 %)
EPS:	$1.010

Financial Reports:

No articles found.

Supernus Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.